Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 40

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 40
---
 the potential economic impact
brought by, and the duration of, any future resurgence of the COVID-19 pandemic may be difficult to assess or predict, it has already
caused, and could result in further, significant disruption of global financial markets, reducing our ability to access capital, which
could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other companies have been
highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our Ordinary
Shares or other securities and such sales may be on unfavorable terms. To the extent that future waves of COVID-19 disrupt normal business
operations, we may face operational challenges with our services, and we likely will have to adopt remote working and workplace protocols
for employees in accordance with government requirements and other measures to minimize such impact.

The
extent to which COVID-19 impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain COVID-19 or treat
its impact. In particular, the extent to which any resurgence of the COVID-19 pandemic may impact our business and financial performance
will depend on future developments, which are highly uncertain and cannot be predicted with confidence.

<div align='center'>25</div>

Risks Related to Our Reliance on Third Parties

We will rely on third parties to conduct certain elements of our preclinical studies and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.

We rely upon third-party vendors,
including CROs, to monitor and manage data for our ongoing preclinical studies and clinical trials. If our CROs do not successfully carry
out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the
clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other
reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully
commercialize our product candidates. We rely on these CROs for execution of our preclinical studies and clinical trials, and we control
only certain aspects of their activities. Nevertheless, we are